Differential roles of uPAR in peritoneal ovarian carcinomatosis

Nada N. Al-Hassan, Ali Behzadian, Ruth B Caldwell, Vessela S. Ivanova, Viqar Syed, Kouros Motamed, Neveen A. Said

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Epithelial ovarian cancer is the fourth leading cause of death from gynecologic malignancies in the United States. Most cases are diagnosed at late stages, with the solid tumor masses growing as peritoneal implants, or floating within the ascitic fluid (peritoneal ovarian carcinomatosis). Despite aggressive surgical "debulking," recurrence of recalcitrant disease is frequent with poor patient survival. Efforts to improve survival rates are hindered by lack of biomarkers that can detect and effectively treat ovarian cancer in its early stages. Urokinase plasminogen activator receptor (uPAR) is a multifunctional receptor involved in a myriad of tumor cell processes. However, the role of host uPAR in ovarian cancer is still elusive. To define the potential proinflammatory role of uPAR in ovarian cancer, first, using a syngeneic murine model in uPAR-/- mice, we found that ablation of uPAR restrained tumor take and peritoneal implants and prolonged the survival of uPAR-/- mice compared with their uPAR+/+ counterparts. Ascitic fluid accumulation was significantly decreased in uPAR-/- mice with decreased macrophage infiltration. Second, in vitro mechanistic studies revealed that host uPAR is involved in the multiple steps of peritoneal metastatic cascade. Third, we evaluated the prognostic utility of tumor and stromal uPAR in human ovarian cancer tissue microarray. In summary, our studies indicated that uPAR plays a significant role in ovarian cancer cell-stromal crosstalk and contributes to increased vascular permeability and inflammatory ovarian cancer microenvironment. This provides a rationale for targeting the uPAR with either specific neutralizing antibodies or targeting its downstream inflammatory effectors in patients with ovarian cancer.

Original languageEnglish (US)
Pages (from-to)259-270
Number of pages12
JournalNeoplasia
Volume14
Issue number4
DOIs
StatePublished - Jan 1 2012

Fingerprint

Urokinase Plasminogen Activator Receptors
Ovarian Neoplasms
Carcinoma
Ascitic Fluid
Neoplasms
Tumor Microenvironment
Survival
Capillary Permeability
Stromal Cells
Neutralizing Antibodies
Cause of Death
Survival Rate
Biomarkers
Macrophages
Recurrence

ASJC Scopus subject areas

  • Cancer Research

Cite this

Al-Hassan, N. N., Behzadian, A., Caldwell, R. B., Ivanova, V. S., Syed, V., Motamed, K., & Said, N. A. (2012). Differential roles of uPAR in peritoneal ovarian carcinomatosis. Neoplasia, 14(4), 259-270. https://doi.org/10.1593/neo.12442

Differential roles of uPAR in peritoneal ovarian carcinomatosis. / Al-Hassan, Nada N.; Behzadian, Ali; Caldwell, Ruth B; Ivanova, Vessela S.; Syed, Viqar; Motamed, Kouros; Said, Neveen A.

In: Neoplasia, Vol. 14, No. 4, 01.01.2012, p. 259-270.

Research output: Contribution to journalArticle

Al-Hassan, NN, Behzadian, A, Caldwell, RB, Ivanova, VS, Syed, V, Motamed, K & Said, NA 2012, 'Differential roles of uPAR in peritoneal ovarian carcinomatosis', Neoplasia, vol. 14, no. 4, pp. 259-270. https://doi.org/10.1593/neo.12442
Al-Hassan NN, Behzadian A, Caldwell RB, Ivanova VS, Syed V, Motamed K et al. Differential roles of uPAR in peritoneal ovarian carcinomatosis. Neoplasia. 2012 Jan 1;14(4):259-270. https://doi.org/10.1593/neo.12442
Al-Hassan, Nada N. ; Behzadian, Ali ; Caldwell, Ruth B ; Ivanova, Vessela S. ; Syed, Viqar ; Motamed, Kouros ; Said, Neveen A. / Differential roles of uPAR in peritoneal ovarian carcinomatosis. In: Neoplasia. 2012 ; Vol. 14, No. 4. pp. 259-270.
@article{ba9686e605dc46589b4f59b0464b1463,
title = "Differential roles of uPAR in peritoneal ovarian carcinomatosis",
abstract = "Epithelial ovarian cancer is the fourth leading cause of death from gynecologic malignancies in the United States. Most cases are diagnosed at late stages, with the solid tumor masses growing as peritoneal implants, or floating within the ascitic fluid (peritoneal ovarian carcinomatosis). Despite aggressive surgical {"}debulking,{"} recurrence of recalcitrant disease is frequent with poor patient survival. Efforts to improve survival rates are hindered by lack of biomarkers that can detect and effectively treat ovarian cancer in its early stages. Urokinase plasminogen activator receptor (uPAR) is a multifunctional receptor involved in a myriad of tumor cell processes. However, the role of host uPAR in ovarian cancer is still elusive. To define the potential proinflammatory role of uPAR in ovarian cancer, first, using a syngeneic murine model in uPAR-/- mice, we found that ablation of uPAR restrained tumor take and peritoneal implants and prolonged the survival of uPAR-/- mice compared with their uPAR+/+ counterparts. Ascitic fluid accumulation was significantly decreased in uPAR-/- mice with decreased macrophage infiltration. Second, in vitro mechanistic studies revealed that host uPAR is involved in the multiple steps of peritoneal metastatic cascade. Third, we evaluated the prognostic utility of tumor and stromal uPAR in human ovarian cancer tissue microarray. In summary, our studies indicated that uPAR plays a significant role in ovarian cancer cell-stromal crosstalk and contributes to increased vascular permeability and inflammatory ovarian cancer microenvironment. This provides a rationale for targeting the uPAR with either specific neutralizing antibodies or targeting its downstream inflammatory effectors in patients with ovarian cancer.",
author = "Al-Hassan, {Nada N.} and Ali Behzadian and Caldwell, {Ruth B} and Ivanova, {Vessela S.} and Viqar Syed and Kouros Motamed and Said, {Neveen A.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1593/neo.12442",
language = "English (US)",
volume = "14",
pages = "259--270",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Differential roles of uPAR in peritoneal ovarian carcinomatosis

AU - Al-Hassan, Nada N.

AU - Behzadian, Ali

AU - Caldwell, Ruth B

AU - Ivanova, Vessela S.

AU - Syed, Viqar

AU - Motamed, Kouros

AU - Said, Neveen A.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Epithelial ovarian cancer is the fourth leading cause of death from gynecologic malignancies in the United States. Most cases are diagnosed at late stages, with the solid tumor masses growing as peritoneal implants, or floating within the ascitic fluid (peritoneal ovarian carcinomatosis). Despite aggressive surgical "debulking," recurrence of recalcitrant disease is frequent with poor patient survival. Efforts to improve survival rates are hindered by lack of biomarkers that can detect and effectively treat ovarian cancer in its early stages. Urokinase plasminogen activator receptor (uPAR) is a multifunctional receptor involved in a myriad of tumor cell processes. However, the role of host uPAR in ovarian cancer is still elusive. To define the potential proinflammatory role of uPAR in ovarian cancer, first, using a syngeneic murine model in uPAR-/- mice, we found that ablation of uPAR restrained tumor take and peritoneal implants and prolonged the survival of uPAR-/- mice compared with their uPAR+/+ counterparts. Ascitic fluid accumulation was significantly decreased in uPAR-/- mice with decreased macrophage infiltration. Second, in vitro mechanistic studies revealed that host uPAR is involved in the multiple steps of peritoneal metastatic cascade. Third, we evaluated the prognostic utility of tumor and stromal uPAR in human ovarian cancer tissue microarray. In summary, our studies indicated that uPAR plays a significant role in ovarian cancer cell-stromal crosstalk and contributes to increased vascular permeability and inflammatory ovarian cancer microenvironment. This provides a rationale for targeting the uPAR with either specific neutralizing antibodies or targeting its downstream inflammatory effectors in patients with ovarian cancer.

AB - Epithelial ovarian cancer is the fourth leading cause of death from gynecologic malignancies in the United States. Most cases are diagnosed at late stages, with the solid tumor masses growing as peritoneal implants, or floating within the ascitic fluid (peritoneal ovarian carcinomatosis). Despite aggressive surgical "debulking," recurrence of recalcitrant disease is frequent with poor patient survival. Efforts to improve survival rates are hindered by lack of biomarkers that can detect and effectively treat ovarian cancer in its early stages. Urokinase plasminogen activator receptor (uPAR) is a multifunctional receptor involved in a myriad of tumor cell processes. However, the role of host uPAR in ovarian cancer is still elusive. To define the potential proinflammatory role of uPAR in ovarian cancer, first, using a syngeneic murine model in uPAR-/- mice, we found that ablation of uPAR restrained tumor take and peritoneal implants and prolonged the survival of uPAR-/- mice compared with their uPAR+/+ counterparts. Ascitic fluid accumulation was significantly decreased in uPAR-/- mice with decreased macrophage infiltration. Second, in vitro mechanistic studies revealed that host uPAR is involved in the multiple steps of peritoneal metastatic cascade. Third, we evaluated the prognostic utility of tumor and stromal uPAR in human ovarian cancer tissue microarray. In summary, our studies indicated that uPAR plays a significant role in ovarian cancer cell-stromal crosstalk and contributes to increased vascular permeability and inflammatory ovarian cancer microenvironment. This provides a rationale for targeting the uPAR with either specific neutralizing antibodies or targeting its downstream inflammatory effectors in patients with ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=84860611297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860611297&partnerID=8YFLogxK

U2 - 10.1593/neo.12442

DO - 10.1593/neo.12442

M3 - Article

VL - 14

SP - 259

EP - 270

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 4

ER -